SHR-2010 injection

DRUG2 trials

Sponsors

Guangdong Hengrui Pharmaceutical Co., Ltd

Conditions

IgA NephropathyPrimary IgA Nephropathy

Phase 1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject

CompletedNCT05398510

Guangdong Hengrui Pharmaceutical Co., LtdIgA Nephropathy

Start: 2022-06-30End: 2023-03-10Updated: 2023-03-23

Phase 2

Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy

TerminatedNCT05847920

Guangdong Hengrui Pharmaceutical Co., LtdPrimary IgA Nephropathy

Start: 2023-06-04End: 2025-01-20Updated: 2025-03-05

Related Papers

Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study

Expert Opinion on Investigational Drugs2025-04-03